Apyx Medical Beheer

Beheer criteriumcontroles 2/4

De CEO Apyx Medical is Charlie Goodwin, benoemd in Dec2017, heeft een ambtstermijn van 6.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.26M, bestaande uit 38.2% salaris en 61.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.24% van de aandelen van het bedrijf, ter waarde € 123.91K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 5.3 jaar.

Belangrijke informatie

Charlie Goodwin

Algemeen directeur

US$1.3m

Totale compensatie

Percentage CEO-salaris	38.2%
Dienstverband CEO	6.9yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	5.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Charlie Goodwin's beloning veranderd ten opzichte van Apyx Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$1m	US$483k	-US$19m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$2m	US$483k	-US$23m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$2m	US$450k	-US$15m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$14m
Mar 31 2021	n/a	n/a	-US$15m
Dec 31 2020	US$2m	US$450k	-US$12m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$2m	US$450k	-US$20m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$400k	-US$11m
Sep 30 2018	n/a	n/a	-US$10m
Jun 30 2018	n/a	n/a	-US$12m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$2m	US$15k	-US$14m

Compensatie versus markt: De totale vergoeding ($USD 1.26M ) Charlie } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van Charlie is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Charlie Goodwin (58 yo)

6.9yrs

Tenure

US$1,261,470

Compensatie

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Charles Goodwin	President	6.9yrs	US$1.26m	0.24% € 123.9k
Matthew Hill	CFO, Treasurer & Secretary	less than a year	US$445.95k	0.021% € 10.8k
Moshe Citronowicz	Senior Vice President	12.8yrs	US$538.31k	1.21% € 628.5k
Stavros Vizirgianakis	Executive Chairman	less than a year	geen gegevens	4.64% € 2.4m
Shawn Roman	Chief Operating Officer	no data	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BOV wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Charles Goodwin	President	6.9yrs	US$1.26m	0.24% € 123.9k
Stavros Vizirgianakis	Executive Chairman	less than a year	geen gegevens	4.64% € 2.4m
Lawrence Waldman	Lead Independent Director	13.7yrs	US$162.56k	0.11% € 59.1k
Brian Kinney	Member of Medical Advisory Board	5.3yrs	geen gegevens	geen gegevens
Gregory Konesky	Member of Scientific Advisory Board	no data	US$9.30k	geen gegevens
Yuval Carmel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Minnie Baylor-Henry	Independent Director	5.3yrs	US$116.56k	0% € 0
Dennis Chi	Member of Medical Advisory Board	7.8yrs	geen gegevens	geen gegevens
Diane Duncan	Member of Medical Advisory Board	6.5yrs	geen gegevens	geen gegevens
Paul Ruff	Member of Medical Advisory Board	5.3yrs	geen gegevens	geen gegevens
Richard Gentile	Member of Medical Advisory Board	5.3yrs	geen gegevens	geen gegevens
Edward Zimmerman	Member of Medical Advisory Board	5.3yrs	geen gegevens	geen gegevens

5.3yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BOV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).

Apyx Medical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

President recently bought €72k worth of stock

Apyx Medical Corporation, Annual General Meeting, Aug 10, 2023

Recent updates

Now 21% undervalued after recent price drop

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.13 loss in 3Q 2023)

Apyx Medical Corporation has filed a Follow-on Equity Offering in the amount of $7 million.

Apyx Medical Corporation has filed a Follow-on Equity Offering in the amount of $7 million.

Apyx Medical Corporation to Report Q3, 2024 Results on Nov 08, 2024

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.19 loss per share (vs US$0.029 loss in 2Q 2023)

Apyx Medical Corporation Revises Earnings Guidance for the Full Year Ended December 31, 2024

Apyx Medical Corporation to Report Q2, 2024 Results on Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Apyx Medical Corporation, Annual General Meeting, Aug 08, 2024

Now 37% overvalued

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.10 loss in 1Q 2023)

Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024

New major risk - Revenue and earnings growth

Apyx Medical Corporation to Report Q1, 2024 Results on May 09, 2024

Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings released: US$0.54 loss per share (vs US$0.67 loss in FY 2022)

Apyx Medical Corporation to Report Q4, 2023 Results on Mar 21, 2024

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

New major risk - Revenue and earnings growth

Apyx Medical Corporation Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer, Effective December 4, 2023

Apyx Medical Corporation Announces Resignation of Tara Semb as Chief Financial Officer

President recently bought €72k worth of stock

Apyx Medical Corporation Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.17 loss in 3Q 2022)

New minor risk - Market cap size

Apyx Medical Corporation to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

Apyx Medical Corporation Reaffirms Financial Guidance for the Year Ending December 31, 2023

Second quarter 2023 earnings released: US$0.029 loss per share (vs US$0.16 loss in 2Q 2022)

Apyx Medical Corporation to Report Q2, 2023 Results on Aug 10, 2023

Apyx Medical Corporation, Annual General Meeting, Aug 10, 2023

Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.17 loss in 1Q 2022)

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2023

Full year 2022 earnings released: US$0.67 loss per share (vs US$0.44 loss in FY 2021)

Apyx Medical Corporation to Report Q4, 2022 Results on Mar 16, 2023

Apyx Medical Corporation Announces FDA 510(K) Submission for the Use of the Renuvion® Apr. Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction

Apyx Medical Corporation Launches New 'Apyx One Console' for Cosmetic Surgical Procedures in the United States

Apyx Medical Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.12 loss in 3Q 2021)

Apyx Medical Corporation Updates Earnings Guidance for the Year Ending December 31, 2022

Apyx Medical Corporation to Report Q3, 2022 Results on Nov 10, 2022

Insufficient new directors

President recently bought €70k worth of stock

Second quarter 2022 earnings released

Apyx Medical Corporation Updates Earnings Guidance for the Full Year Ending December 31, 2022

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apyx Medical Corporation

Apyx Medical Corporation Announces Results of the U.S. Ide Clinical Study Evaluating the Use of Renuvion to Improve the Appearance of Lax Skin in the Neck and Submental Region

Apyx Medical Corporation to Report Q2, 2022 Results on Aug 11, 2022

Apyx Medical Corporation Announces Receipt of 510(K) Clearance from FDA for Use of the Renuvion Dermal Handpiece for Specific Dermatological Procedures for Treatment of Moderate to Severe Wrinkles and Rhytides, Limited to Patients with Fitzpatrick Skin Types I, II or III

Apyx Medical Corporation(NasdaqGS:APYX) dropped from Russell 3000E Growth Index

Apyx Medical Corporation, Annual General Meeting, Aug 11, 2022

William E. Hattaway, Files A Complaint Against Apyx Medical Corporation

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Apyx Medical Corporation

Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® Cosmetic Technology in Dermal Resurfacing Procedures

First quarter 2022 earnings released: US$0.17 loss per share (vs US$0.14 loss in 1Q 2021)

Apyx Medical Corporation Updates Financial Guidance for the Year Ending December 31, 2022

Apyx Medical Corporation Announces FDA 510(K) Submission with Clinical Study Support for the Use of the Renuvion® APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 49% undervalued after recent price drop

Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study Evaluating the Renuvion® Dermal Handpiece Using Apyx’s Helium Plasma Technology for Dermal Resurfacing Procedures

Apyx Medical Corporation to Report Q4, 2021 Results on Mar 17, 2022

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.11 loss in 3Q 2020)